antiparisitic drugs Flashcards
malaria parasite
Plasmodium falciparum - Responsible for most malaria deaths
Plasmodium vivax - Relapsing malaria - caused by hypnozoites in liver
Plasmodium ovale - Relapsing
Plasmodium malariae (72 h life cycle)
Plasmodium knowlesi
uncomplicated malaria
Classic symptoms -Cold stage -Hot stage -Sweating stage -48 hour periodicity for Falciparum and Vivax malaria More usual symptoms -Fever and flu-like symptoms - chills, headache, myalgias, and malaise -Anemia and jaundice
severe malaria
Serious organ failures, including kidney Cerebral malaria -abnormal behavior, impairment of consciousness, seizures, coma, or other neurologic abnormalities Severe anemia and hemoglobinuria (hemoglobin in the urine) due to hemolysis Acute respiratory distress syndrome Placental malaria -Especially during first pregnancy -Causes low birth weight and miscarriage
malaria chemoprophylaxis
Prevention! - Insect repellents, Insecticides, Bed nets
Chemoprophylaxis
-Should be taken before, during and after travel,
-Consult the CDC Travel Vaccines & Malaria Information, by Country
Factors to consider: Species present, Level and type of drug resistance, Lead time before travel
Common options
-Atovaquone-proguanil or doxycycline - Daily admin + short pretreatment
Chloroquine – only if sensitive parasites
Mefloquine – weekly admin, good for long trips
Primaquine – if >90% P. vivax in area
antimalarial drugs
Drug classification
-Tissue schizonticides - kill liver stage parasites
-Blood schizonticides - kill erythrocytic forms
-Gametocytocides - Kill sexual stages; Block transmission
No single drug is active against all stages
Multiple drugs may be necessary
Artemisinin
4-aminoquinolines
8-aminoquinolines
Atovaquone
Antifolates
Antibiotics
artemisinin
Sesquiterpene lactone endoperoxide - Endoperoxide is active group
Potent and fast acting - 10,000-fold reduction in 48 h
Low toxicity
Counterfeits are common
Rapidly acting blood schizonticide
Kills liver stage, but not hypnozoites
short half-life – 1-2 h - recrudescence rate is high after short course of treatment; Not appropriate for chemoprophylaxsis
Commonly paired with other drugs - Mefloquine or lumefantrine frequently used
artemisinin MOA and MOR
Mechanism of action
-Must be activated – likely via heme-iron
-Activated artemisinin may form free radicals - Target parasite proteins and lipids (phosphatidylinositol-3-kinase (PfPI3K) is a direct target, but more are likely)
Mechanism of resistance
-Mutations in Kelch 13 gene
-Delays progress through the life cycle
-May alter stress response
artemisinin combo therapy
Artemisinin derivatives are paired with longer half-life drugs - Artemisinin provides rapid knockdown; Longer half-life component eliminates remaining parasites Combinations -Lumefantrine most common (Coartem) -amodiaquine -mefloquine -piperaquine
artemisinin PKs
Artemisinin is insoluble
-Can only be used orally
-low bioavailability
semisynthetic artemisinins are available
-different routes of administration
—oral (dihydroartemisinin, artesunate, and artemether)
—intramuscular (artesunate and artemether)
—intravenous (artesunate)
—rectal (artesunate)
Artesunate now available in U.S. via CDC for treatment of severe malaria
Artemether - Converted to dihydroartemisinin by CYPs (CYP3A4»_space; CYP2B6, CYP2C9, CYP2C19)
Artesunate - Converted to dihydroartemisinin by by plasma esterases (and possibly CYP2A6)
Dihydroartemisinin glucuronidated in gut and liver – excreted in urine
antimalarial effect associated with Cmax (bolus better than infusion)
4-aminoquinolines examples
quinine, chloroquine, mefloquine
hbg metabolism
Malaria parasites ingest hemoglobin from host cell
Degrade hemoglobin to amino acids and free heme in food vacuole
Free heme is toxic
Parasite polymerizes heme into hemozoin, which is nontoxic
Chloroquine accumulates in food vacuole and inhibits heme polymerization
4-substituted quinolines
Interfere with heme polymerization
Resistance associated with lack of accumulation in food vacuole
chloroquine
Drug of choice since 1940s
Pharmacokinetics: Formulated for oral use, Well absorbed, Very large volume of distribution (Slowly released from tissues), Initial half-life of 3-5 days; terminal half-life 1-2 months
Note: Hydroxychloroquine more commonly stocked in U. S. pharmacies - Same as CQ, but with a hydroxyl at end of sidechain; More water soluble, but both are soluble
antimalarial effect associated
with T>MIC (infusion better than bolus)
chloroquine resistance
Developed in P. falciparum in at least 2 foci in 1950’s and spread
Primary mechanism: mutations in PfCRT1
-Localized to food vacuole
-Causes reduced accumulation of chloroquine
-No cross-resistance with mefloquine or quinine
Over-expression of PfMDR1 (drug transporter)
P. vivax developed resistance 30 years later and by a different mechanism
quinine
Mechanism thought to be similar to CQ
Resistance rare but increasing
Blood schizonticide
Treatment of choice for:
-Chloroquine-resistant falciparum malaria - Quinine sulfate - orally availableSevere falciparum malaria - quinidine gluconate - administered by IV; Cardiac monitoring should be in place
Shorter half-life and toxicity make it inappropriate for chemoprophylaxis
Adverse effects
-Cinchonism: tinnitis, headache, nausea, dizziness, flushing, & visual disturbances
-Can stimulate uterine contractions
-Hemolysis: G6PD deficiency, Blackwater fever - rare, severe, marked by hemoglobinuria
Metabolized by CYP3A4 - can raise levels of warfarin and digoxin
Severe hypotension can occur from too-rapid infusion
primaquine
8-aminoquinoline
Metabolized by by the cytochrome P450 (CYP) 2D6 in humans - Metabolism required for activity, Mechanism may involve free radicals
Drug of choice for liver stages (actively growing and hypnozoites) of P. vivax and P. ovale* (in combination
with chloroquine)
Tafenoquine is a related compound - Same spectrum of activity, Same toxicities, does not seem to be affected by CYP2D6 polymorphisms
Well absorbed orally
Some resistance has been noted
High risk of hemolysis in patients with G6PD deficiency - Establish normal G6PD levels before use; Use with caution if G6PD deficient - Discontinue if indication of hemolytic anemia
Should not be used in pregnant women - If breast feeding – CDC, no restrictions if G6PD normal (UK recommends avoiding)
Contraindications: Granulocytopenia, Concurrent use of other potentially hemolytic drugs or drugs that suppress myeloid cell development
malarone
Combination of proguanil and atovaquone
-Atovaquone failed as monotherapy - resistance developed rapidly
-Combination is synergistic
Kills liver and blood stages (but not hypnozoites)
-Effective as treatment for uncomplicated malaria and chemoprophylaxsis - Atovaquone also used to treat Toxoplasma gondii and Pneumocystis jiroveci
atovaquone
Selective inhibitor of malaria mitochondrial cytochrome bc1 complex - inhibits electron transport, mitochondrial membrane potential collapses
Main role for mitochondrial electron transport in P. falciparum - regenerate ubiquinone
-Atovaquone is a ubiquinone analog
-electron acceptor for parasite dihydroorotate dehydrogenase - essential for pyrimidine biosynthesis in the parasite
proguanil
Converted to cycloguanil
-selective inhibitor of the bifunctional plasmodial dihydrofolate reductase-thymidylate synthetase
-crucial for parasite purine and pyrimidine synthesis
Proguanil also has inherent antimalarial activity
-Enhances mitochondrial toxicity of atavaquone
pyrimethamine sulfadoxine
Folate synthesis inhibitors
Slow acting erythrocytic schizonticides
Similar combination used to treat Toxoplasmosis
Pyrimethamine – inhibits plasmodia DHF reductase (1,000-fold selectivity for Plasmodium)
other uses of antifolates
Toxoplasmosis
-Pyrimethamine plus sulfadiazine is first-line therapy - Clindamycin can replace sulfadiazine
Pneumocystis
-trimethoprim plus sulfamethoxazole is first-line therapy
-Atavaquone is alternative